Q1 FY27 transcript: PAT up 65%, 10% constant currency growth
DIVISLAB · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Divi's Labs Q1 FY27 consolidated PAT rose to 902 cr from 545 cr year-on-year, total income 3,144 cr versus 2,529 cr. Standalone revenue grew 10% in constant currency. Custom Synthesis contributed 60% of revenue, Generics 40%. Exports at about 90% of standalone revenue. Three major capex projects about 70% complete with capitalization of about 2,000 cr done. Plant utilization around 80 to 85 percent across all 3 units. Management reiterated double-digit growth guidance, full year gross margin around 60%, EBITDA margin similar to last year. Solvent costs remain elevated due to West Asia situation. Nutraceutical revenue 298 cr. Cash and equivalents 3,611 cr.
Strong earnings beat with double-digit growth reaffirmed. Solvent cost pressure and project lumpiness remain near-term watch points. Capex nearing completion.